Toxoplasmosis Treatment Market by Type (Acquired Toxoplasmosis and Congenital Toxoplasmosis), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies and Online Providers) and Geography (North America, Europe, APAC and RoW)-Forecast up to 2027
Toxoplasmosis is an infection caused due to a common parasite, which is present in cat feces and in contaminated food. This parasite is referred as Toxoplasma gondii. The symptoms of toxoplasmosis disease are headache, body aches and pain, fever, fatigue, and swollen lymph nodes. Apart from this, the people with weakened immune system who receive chemotherapy, a preceding toxoplasma infection may arise and cause the symptoms such as confusion, poor coordination, headache, and seizures. The growing prevalence of toxoplasmosis is the key factor propelling the market growth. The incidence of toxoplasmosis is on the rise, majorly owing to the rise in the number of people with low immune systems, such as cancer patients, HIV/AIDS patients, and transplant recipients. This is propelling the demand for effective treatments for the disease. In addition to this, the rise in awareness about foodborne illness accelerates the growth of toxoplasmosis treatment market. On the other hand, the negative effects of the drugs may negatively impact the toxoplasmosis treatment market growth. The Toxoplasmosis Treatment Market is expected to grow at a rate of 4.3% CAGR by 2027.
Toxoplasmosis Treatment Market by Type
Acquired Toxoplasmosis
Congenital Toxoplasmosis
Toxoplasmosis Treatment Market by Route of Administration
Oral
Parenteral
Toxoplasmosis Treatment Market by Distribution Channel
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers
Toxoplasmosis Treatment Market by Geography
North America
Europe
Asia Pacific
Rest of the World
As in the Toxoplasmosis Treatment market for type is segmented into acquired toxoplasmosis and congenital toxoplasmosis. The acquired toxoplasmosis segment has acquired a significant share in the market. This is due to the increase in incidence of parasitic infection which causes acquired toxoplasmosis. Further, the congenital toxoplasmosis segment is anticipated to register highest CAGR over the forecast period.
On the basis of route of distribution segmentation the Toxoplasmosis Treatment market is bifurcated into Oral and Parenteral. Compared to parenteral, the oral segment dominated the market with highest share. This can be attributed to the increased adoption of oral drugs owing to noninvasive, high patient compliance, easy to handle, and does not need any specific sterile conditions.
In terms of distribution channel, the market is divided into Hospital Pharmacies, Drug Stores and Retail Pharmacies and Online Providers. The hospital pharmacies segment holds the maximum share of the market. The maximum share of the segment is ascribed to the availability of toxoplasmosis drugs and increase in number of hospital pharmacies to treat the toxoplasmosis disease.
In accordance to the regional analysis, the market is segmented into North America, Europe, Asia Pacific and Rest of the World. The North America region is anticipated to lead the market due to the presence of leading players, increase in government initiatives, well-developed healthcare infrastructure, and rise in occurrence of cancer disease which causes toxoplasmosis.
In addition, the healthcare organizations, governments, and non-profit organizations across the world are working to raise awareness regarding the dangers of toxoplasmosis disease and the prominence of early diagnosis and treatment. This is resulting in more people looking for medical attention and accelerating the demand for effective treatments. Thus, the rising awareness regarding the toxoplasmosis disease is vitally driving the global market growth. Apart from this, the increase in chemotherapy procedures can result in growth in number of toxoplasmosis infection, therefore, this highlights the requirement for the toxoplasmosis treatment for the patient, leading to the growth of the market.
Prominent players of the toxoplasmosis treatment market are Teva Pharmaceutical Industries Limited, Mangalam Drugs and Organics Ltd., Zorish Healthcare Private Limited, Alvogen, Dr Reddy's Laboratories Ltd., Vyera Pharmaceuticals LLC, Oakrum Pharma, Kaiser Permanente, omicron pharmaceuticals, and Manus Aktteva Biopharma LLP.
Henceforth, now-a-days the trend of pets in home is rising highly which leads to the increased pets related diseases among humans. Thus, this factor is majorly leading to the increased occurrence of toxoplasmosis disease in humans which eventually contributes to growth of the market growth.
This study represents the key manufacturers, presenting of sales, revenue, market size and new developments for major players.
This study analyzes the global and key geographical regions market prospective and advantages, opportunities and challenges, constraints and risks.
This report further depicts the important trends, drivers, impacting factors of the toxoplasmosis treatment
This report represents the competitive outlook in terms of expansions, agreements, new product launches and acquisitions in the toxoplasmosis treatment
Toxoplasmosis Treatment Market by Type
Acquired Toxoplasmosis
Congenital Toxoplasmosis
Toxoplasmosis Treatment Market by Route of Administration
Oral
Parenteral
Toxoplasmosis Treatment Market by Distribution Channel
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers
Toxoplasmosis Treatment Market by Geography
North America
Europe
Asia Pacific
Rest of the World
As in the Toxoplasmosis Treatment market for type is segmented into acquired toxoplasmosis and congenital toxoplasmosis. The acquired toxoplasmosis segment has acquired a significant share in the market. This is due to the increase in incidence of parasitic infection which causes acquired toxoplasmosis. Further, the congenital toxoplasmosis segment is anticipated to register highest CAGR over the forecast period.
On the basis of route of distribution segmentation the Toxoplasmosis Treatment market is bifurcated into Oral and Parenteral. Compared to parenteral, the oral segment dominated the market with highest share. This can be attributed to the increased adoption of oral drugs owing to noninvasive, high patient compliance, easy to handle, and does not need any specific sterile conditions.
In terms of distribution channel, the market is divided into Hospital Pharmacies, Drug Stores and Retail Pharmacies and Online Providers. The hospital pharmacies segment holds the maximum share of the market. The maximum share of the segment is ascribed to the availability of toxoplasmosis drugs and increase in number of hospital pharmacies to treat the toxoplasmosis disease.
In accordance to the regional analysis, the market is segmented into North America, Europe, Asia Pacific and Rest of the World. The North America region is anticipated to lead the market due to the presence of leading players, increase in government initiatives, well-developed healthcare infrastructure, and rise in occurrence of cancer disease which causes toxoplasmosis.
In addition, the healthcare organizations, governments, and non-profit organizations across the world are working to raise awareness regarding the dangers of toxoplasmosis disease and the prominence of early diagnosis and treatment. This is resulting in more people looking for medical attention and accelerating the demand for effective treatments. Thus, the rising awareness regarding the toxoplasmosis disease is vitally driving the global market growth. Apart from this, the increase in chemotherapy procedures can result in growth in number of toxoplasmosis infection, therefore, this highlights the requirement for the toxoplasmosis treatment for the patient, leading to the growth of the market.
Prominent players of the toxoplasmosis treatment market are Teva Pharmaceutical Industries Limited, Mangalam Drugs and Organics Ltd., Zorish Healthcare Private Limited, Alvogen, Dr Reddy's Laboratories Ltd., Vyera Pharmaceuticals LLC, Oakrum Pharma, Kaiser Permanente, omicron pharmaceuticals, and Manus Aktteva Biopharma LLP.
Henceforth, now-a-days the trend of pets in home is rising highly which leads to the increased pets related diseases among humans. Thus, this factor is majorly leading to the increased occurrence of toxoplasmosis disease in humans which eventually contributes to growth of the market growth.
This study represents the key manufacturers, presenting of sales, revenue, market size and new developments for major players.
This study analyzes the global and key geographical regions market prospective and advantages, opportunities and challenges, constraints and risks.
This report further depicts the important trends, drivers, impacting factors of the toxoplasmosis treatment
This report represents the competitive outlook in terms of expansions, agreements, new product launches and acquisitions in the toxoplasmosis treatment
1. EXECUTIVE SUMMARY
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. TYPE: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Acquired Toxoplasmosis
5.3. Congenital Toxoplasmosis
6. ROUTE OF ADMINISTRATION: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Oral
6.3. Parenteral
7. DISTRIBUTION CHANNEL: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. Hospital Pharmacies
7.3. Drug Stores and Retail Pharmacies
7.4. Online Providers
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. Teva Pharmaceutical Industries Limited
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. Mangalam Drugs and Organics Ltd.
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. Zorish Healthcare Private Limited
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. Alvogen
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Dr Reddy's Laboratories Ltd.
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. Vyera Pharmaceuticals LLC
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. Oakrum Pharma
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. Kaiser Permanente
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. omicron pharmaceuticals
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. Manus Aktteva Biopharma LLP
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. ANALYST OPINION
12. ANNEXURE
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. TYPE: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Acquired Toxoplasmosis
5.3. Congenital Toxoplasmosis
6. ROUTE OF ADMINISTRATION: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Oral
6.3. Parenteral
7. DISTRIBUTION CHANNEL: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. Hospital Pharmacies
7.3. Drug Stores and Retail Pharmacies
7.4. Online Providers
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. Teva Pharmaceutical Industries Limited
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. Mangalam Drugs and Organics Ltd.
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. Zorish Healthcare Private Limited
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. Alvogen
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Dr Reddy's Laboratories Ltd.
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. Vyera Pharmaceuticals LLC
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. Oakrum Pharma
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. Kaiser Permanente
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. omicron pharmaceuticals
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. Manus Aktteva Biopharma LLP
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. ANALYST OPINION
12. ANNEXURE
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations
LIST OF TABLES
TABLE 1. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE FOR ACQUIRED TOXOPLASMOSIS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE FOR CONGENITAL TOXOPLASMOSIS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE FOR ORAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE FOR PARENTERAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE FOR HOSPITAL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE FOR DRUG STORES AND RETAIL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE FOR ONLINE PROVIDERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. NORTH AMERICA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 12. NORTH AMERICA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 13. NORTH AMERICA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 14. NORTH AMERICA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 15. U.S TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 16. U.S TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 17. U.S TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 18. CANADA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 19. CANADA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 20. CANADA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 21. EUROPE TOXOPLASMOSIS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 22. EUROPE TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 23. EUROPE TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 24. EUROPE TOXOPLASMOSIS TREATMENT MARKET VALUE, DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 25. GERMANY TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 26. GERMANY TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 27. GERMANY TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 28. U.K TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 29. U.K TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 30. U.K TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 31. FRANCE TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 32. FRANCE TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 33. FRANCE TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 34. ITALY TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 35. ITALY TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 36. ITALY TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 37. SPAIN TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 38. SPAIN TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 39. SPAIN TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 40. ROE TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 41. ROE TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 42. ROE TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 43. ASIA PACIFC TOXOPLASMOSIS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 44. ASIA PACIFC TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 45. ASIA PACIFC TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 46. ASIA PACIFC TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 47. CHINA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 48. CHINA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 49. CHINA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 50. INDIA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 51. INDIA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 52. INDIA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 53. JAPAN TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 54. JAPAN TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 55. JAPAN TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 56. REST OF APAC TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 57. REST OF APAC TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 58. REST OF APAC TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 59. REST OF WORLD TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 60. REST OF WORLD TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 61. REST OF WORLD TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 62. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: FINANCIALS
TABLE 63. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCTS & SERVICES
TABLE 64. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: RECENT DEVELOPMENTS
TABLE 65. MANGALAM DRUGS AND ORGANICS LTD.: FINANCIALS
TABLE 66. MANGALAM DRUGS AND ORGANICS LTD.: PRODUCTS & SERVICES
TABLE 67. MANGALAM DRUGS AND ORGANICS LTD.: RECENT DEVELOPMENTS
TABLE 68. ZORISH HEALTHCARE PRIVATE LIMITED: FINANCIALS
TABLE 69. ZORISH HEALTHCARE PRIVATE LIMITED: PRODUCTS & SERVICES
TABLE 70. ZORISH HEALTHCARE PRIVATE LIMITED: RECENT DEVELOPMENTS
TABLE 71. ALVOGEN: FINANCIALS
TABLE 72. ALVOGEN: PRODUCTS & SERVICES
TABLE 73. ALVOGEN: RECENT DEVELOPMENTS
TABLE 74. DR REDDY'S LABORATORIES LTD.: FINANCIALS
TABLE 75. DR REDDY'S LABORATORIES LTD.: PRODUCTS & SERVICES
TABLE 76. DR REDDY'S LABORATORIES LTD.: RECENT DEVELOPMENTS
TABLE 77. VYERA PHARMACEUTICALS LLC: FINANCIALS
TABLE 78. VYERA PHARMACEUTICALS LLC: PRODUCTS & SERVICES
TABLE 79. VYERA PHARMACEUTICALS LLC: RECENT DEVELOPMENTS
TABLE 80. OAKRUM PHARMA: FINANCIALS
TABLE 81. OAKRUM PHARMA: PRODUCTS & SERVICES
TABLE 82. OAKRUM PHARMA: RECENT DEVELOPMENTS
TABLE 83. KAISER PERMANENTE: FINANCIALS
TABLE 84. KAISER PERMANENTE: PRODUCTS & SERVICES
TABLE 85. KAISER PERMANENTE: RECENT DEVELOPMENTS
TABLE 86. OMICRON PHARMACEUTICALS: FINANCIALS
TABLE 87. OMICRON PHARMACEUTICALS: PRODUCTS & SERVICES
TABLE 88. OMICRON PHARMACEUTICALS: RECENT DEVELOPMENTS
TABLE 89. MANUS AKTTEVA BIOPHARMA LLP: FINANCIALS
TABLE 90. MANUS AKTTEVA BIOPHARMA LLP: PRODUCTS & SERVICES
TABLE 91. MANUS AKTTEVA BIOPHARMA LLP: RECENT DEVELOPMENTS
TABLE 1. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE FOR ACQUIRED TOXOPLASMOSIS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE FOR CONGENITAL TOXOPLASMOSIS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE FOR ORAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE FOR PARENTERAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE FOR HOSPITAL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE FOR DRUG STORES AND RETAIL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE FOR ONLINE PROVIDERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. NORTH AMERICA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 12. NORTH AMERICA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 13. NORTH AMERICA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 14. NORTH AMERICA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 15. U.S TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 16. U.S TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 17. U.S TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 18. CANADA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 19. CANADA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 20. CANADA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 21. EUROPE TOXOPLASMOSIS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 22. EUROPE TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 23. EUROPE TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 24. EUROPE TOXOPLASMOSIS TREATMENT MARKET VALUE, DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 25. GERMANY TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 26. GERMANY TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 27. GERMANY TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 28. U.K TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 29. U.K TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 30. U.K TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 31. FRANCE TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 32. FRANCE TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 33. FRANCE TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 34. ITALY TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 35. ITALY TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 36. ITALY TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 37. SPAIN TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 38. SPAIN TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 39. SPAIN TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 40. ROE TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 41. ROE TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 42. ROE TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 43. ASIA PACIFC TOXOPLASMOSIS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 44. ASIA PACIFC TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 45. ASIA PACIFC TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 46. ASIA PACIFC TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 47. CHINA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 48. CHINA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 49. CHINA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 50. INDIA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 51. INDIA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 52. INDIA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 53. JAPAN TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 54. JAPAN TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 55. JAPAN TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 56. REST OF APAC TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 57. REST OF APAC TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 58. REST OF APAC TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 59. REST OF WORLD TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 60. REST OF WORLD TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 61. REST OF WORLD TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 62. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: FINANCIALS
TABLE 63. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCTS & SERVICES
TABLE 64. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: RECENT DEVELOPMENTS
TABLE 65. MANGALAM DRUGS AND ORGANICS LTD.: FINANCIALS
TABLE 66. MANGALAM DRUGS AND ORGANICS LTD.: PRODUCTS & SERVICES
TABLE 67. MANGALAM DRUGS AND ORGANICS LTD.: RECENT DEVELOPMENTS
TABLE 68. ZORISH HEALTHCARE PRIVATE LIMITED: FINANCIALS
TABLE 69. ZORISH HEALTHCARE PRIVATE LIMITED: PRODUCTS & SERVICES
TABLE 70. ZORISH HEALTHCARE PRIVATE LIMITED: RECENT DEVELOPMENTS
TABLE 71. ALVOGEN: FINANCIALS
TABLE 72. ALVOGEN: PRODUCTS & SERVICES
TABLE 73. ALVOGEN: RECENT DEVELOPMENTS
TABLE 74. DR REDDY'S LABORATORIES LTD.: FINANCIALS
TABLE 75. DR REDDY'S LABORATORIES LTD.: PRODUCTS & SERVICES
TABLE 76. DR REDDY'S LABORATORIES LTD.: RECENT DEVELOPMENTS
TABLE 77. VYERA PHARMACEUTICALS LLC: FINANCIALS
TABLE 78. VYERA PHARMACEUTICALS LLC: PRODUCTS & SERVICES
TABLE 79. VYERA PHARMACEUTICALS LLC: RECENT DEVELOPMENTS
TABLE 80. OAKRUM PHARMA: FINANCIALS
TABLE 81. OAKRUM PHARMA: PRODUCTS & SERVICES
TABLE 82. OAKRUM PHARMA: RECENT DEVELOPMENTS
TABLE 83. KAISER PERMANENTE: FINANCIALS
TABLE 84. KAISER PERMANENTE: PRODUCTS & SERVICES
TABLE 85. KAISER PERMANENTE: RECENT DEVELOPMENTS
TABLE 86. OMICRON PHARMACEUTICALS: FINANCIALS
TABLE 87. OMICRON PHARMACEUTICALS: PRODUCTS & SERVICES
TABLE 88. OMICRON PHARMACEUTICALS: RECENT DEVELOPMENTS
TABLE 89. MANUS AKTTEVA BIOPHARMA LLP: FINANCIALS
TABLE 90. MANUS AKTTEVA BIOPHARMA LLP: PRODUCTS & SERVICES
TABLE 91. MANUS AKTTEVA BIOPHARMA LLP: RECENT DEVELOPMENTS
